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1. Introduction 
Genetically modified mice mimicking the expression of candidate genes implicated in the 
etiology of disease are essential tools not only to demonstrate the role of these genes in 
disease, but also as preclinical platforms for testing new therapies. The absence of mouse 
models of CLL was a problem hindering CLL research for long time. This problem was 
exacerbated because the development of xenograft models of human CLL cells was also 
troublesome as a result of the non-proliferative nature of circulating CLL cells. However, 
this situation has turned around in the last few years, and several groups have generated a 
collection of genetically modified mice of CLL representing different subtypes of the 
disease. These mice not only have provided new insights into the genes and mechanisms 
involved in development and progression of CLL but also reflect the heterogeneity and 
complexity of this disease. In this chapter we will summarize the most defining 
characteristics of the available mouse models of CLL and how they relate to the different 
CLL subtypes seen in human patients.       
2. Chronic lymphocytic leukemia 
Chronic lymphocytic leukemia (CLL) remains as the most common leukemia in Western 
countries with an age-adjusted incidence rate of 4.2 per 100,000 individuals and an age-
adjusted death rate of 1.5 per 100,000 individuals in the United States, according to the 
National Cancer Institute.  CLL shows significant differences in incidence rates by race 
(Whites/Asians ratio of 4.8:1) and gender (male/female ratio of 2:1) (http://seer.cancer. 
gov/csr/1975_2008). 
Several decades ago CLL was defined as an accumulative disease of immunologically 
incompetent lymphocytes (Dameshek, 1967). Nowadays, CLL is described as a disease 
characterized by the accumulation of slowly proliferating CD5+ CD23+ B lymphocytes with 
a surface membrane phenotype of activated B cells and a gene profile related to memory B 
cells (Damle et al., 2002; Klein et al., 2001). The origin of CLL B cells remains unknown, and 
evidence is accumulating suggesting that different B cell types may be the source of CLL 
(Chiorazzi & Ferrarini, 2011). It is however well established that CLL is a heterogeneous 
disease consisting of at least two separate entities, based on phenotypic and genetic features. 
Approximately 50% of CLL patients have transformed B cells with mutations in IgVH genes 
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(Fais et al., 1998; Schroeder & Dighiero, 1994). The rest of the patients have unmutated IgVH 
CLL clones, which correlates with poor prognosis (Damle et al., 1999; Hamblin et al., 1999).  
Exposure to antigens seems to play a role in both malignant transformation in CLL and in 
selection and expansion of more aggressive clones (Damle et al., 2002; Ghia et al., 2008; Klein 
et al., 2001). Mutational status of the expanded clones could be associated with the type of 
antigen inducing the immune response, that is, T-dependent stimulation in germinal center, 
in the case of mutated clones, or T-dependent out of germinal center or T-independent 
stimulation, in the case of unmutated clones (Chiorazzi & Ferrarini, 2003). 
Several genetic alterations are found in CLL, including chromosome translocations and gene 
promoter unmethylation (Coll-Mulet and Gil, 2009; Klein & Dalla-Favera, 2010).  Epigenetic 
changes affecting the expression and function of genes have also been described in CLL 
(Marton et al., 2008; Plass et al., 2007). The variability in the origin of the CLL is also 
reflected in its clinical progression with patients suffering a mild, indolent disease that do 
not need treatment, patients with aggressive disease, and patients that became resistant to 
current treatments.  Therefore, the development of mouse models based on the different 
alterations observed in CLL patients that recapitulate distinctive aspects of specific CLL 
subtypes will help to better understand the molecular mechanisms of CLL transformation 
and disease progression.  
2.1 NZB mice in the crossroad of autoimmunity and CLL 
As indicated above, human CLL cells usually express CD5 on their surface. Naturally 
occurring CD5+ B cells expansions are observed in two strains of New Zealand mice. One of 
these strains is the New Zealand White (NZW) (Hamano et al., 1998), where these CD5+ B-1 
cell expansions might progress to CLL-like disease in a fraction of elder mice. Three major 
susceptibility loci in chromosomes 17 and 13 have been implicated in this abnormal B-1 cell 
proliferation.  The second strain is the New Zealand Black (NZB), where clonal expansions of 
immunosuppresive CD5+ B cells are found in spleens of aged mice. These expansions will 
progress to CLL in a majority of elder mice (Phillips et al., 1992; Raveche, 1990). These two 
mouse strains have provided the first link between CLL and autoimmunity. Indeed, the hybrid 
F1 offspring of NZBxNZW backcrosses spontaneously developed systemic lupus 
erithematosus (SLE)-like disease, with glomerulonephritis caused by IgM depositions and 
higher titers of anti-DNA and anti-erythrocytes antibodies compared to the parental strains 
(Okada et al., 1990; Tokado el al., 1991). In contrast, the NZBxNZW hybrids showed lower 
incidence of B cell malignancies compared to the pure NZB and NZW backgrounds (Scaglione 
et al., 2007). Further studies demonstrated that development of either autoimmunity or CLL-
like disease was dependent on the MHC haplotypes of the parental NZB, NZW and their 
progeny. Thus, MHC heterozygosis predisposed to SLE-like disease while MHC homozygosis 
predisposed to CLL-like disease (reviewed in (Scaglione et al., 2007)).  
Studies aimed to identify loci linked to the development of CLL in NZB mice were carried 
out by Raveche and coworkers (Raveche et al., 2007). These studies led to the identification 
of three loci on chromosomes 14, 18 and 19 implicated in CLL development. Interestingly, 
the locus on NZB chromosome 14 has synteny with human 13q14, which is deleted in 
almost 50% of patients with CLL (see below). This result further stresses the relevance of 
this locus in CLL development. Both the mouse locus on chromosome 14 and the human 
13q14 region harbor the genes encoding miR15a and miR16-1, and both human CLL with 
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13q14 translocations and NZB mouse with CLL-like disease showed reduced expression of 
miR16 (Raveche et al., 2007). However, new studies indicate that other genes in human 
13q14 besides miR15a/16-1 might be also implicated in CLL development and progression 
(Klein et al., 2010). 
Beyond the identification of the genetic alterations in the NZB and NZW mice responsible 
for disease, these mice provide a unique tool to understand how the lymph node 
microenvironment and cytokines might influence the development of either SLE or CLL. 
Several studies carried out in the NZB and NZW mice have shown that cytokines play 
distinct roles in SLE and CLL development. In this regard, Ramachandra and coworkers 
(Ramachandra et al., 1996) demonstrated that high interleukin (IL)-10 levels in NZB mice 
were correlated with B-1 cell transformation. In agreement with a role for IL-10 in CLL 
development in this mouse model, IL-10 depletion achieved either by targeting deletion of 
the IL-10 gene (Czarneski et al., 2004) or by in vivo administration of antisense IL-10 (Parker 
et al., 2000; Peng et al., 1995) delayed, and even prevented, CLL development. IL-5 is 
another member of the IL family that seems to play an important role as a switch for SLE or 
CLL development. Several studies (Herron et al., 1988; Kanno et al., 1992; Umland et al., 
1989) have shown that B-1 cells in (NZBxNZW)F1 mice are hyper-responsive to IL-5. 
Indeed, in vitro activation of (NZBxNZW)F1 B-1 cells with IL-5 results in B-1 cells 
differentiation to Mott cells (Jiang et al., 1997) and IgM overproduction (Herron et al., 1988; 
Kanno et al., 1992; Umland et al., 1989), strongly suggesting that IL-5 overproduction might 
exacerbate the disease. To prove the role of IL-5 in SLE, Wen and coworkers (Wen et al., 
2004) generated (NZBxNZW)F1 congenic for an IL-5 transgene. Contrary to expectations, 
these mice showed a significant amelioration of SLE symptoms but increased incidence of B 
cell malignancy. Indeed, 40% of these mice exhibited an anomalous accumulation of B-1 
cells that by month 20 met the criteria for CLL.   
The relevance of the New Zealand mouse strains, and particularly the NZB strain, as a CLL 
model can be summarized in these characteristics: 1) it is a naturally occurring model of late 
onset CLL that resembles familiar CLL; 2) transformed B cells are B220lowIgMhighCD5+, they 
express zeta-chain associated protein kinase (ZAP)-70 and have germline Ig sequence; 3) 
transformed cells show DNA repair defects and chromosomal instability; 4) the mice 
develop clinical features also observed in CLL patients, such as autoimmune hemolytic 
anemia; 5) it provides a unique model for studying the relation between CLL and 
autoimmunity; and 6) CLL developed by these mice could be transplanted into recipient 
mice, which makes it suitable for preclinical studies (Scaglione et al., 2007).  The 
identification of the gene(s) accounting for CLL and/or SLE predisposition in these mouse 
strains and also of the extrinsic factors influencing whether CLL or SLE is developed would 
be a breakthrough in our understanding of the mechanisms governing autoimmunity and 
tumorigenesis. 
2.2 The IgH-E-Tcl-1 transgenic mouse as a model of aggressive CLL 
The proto-oncogene T cell leukemia (TCL)-1 family is composed by three isoforms: TCL-1, 
TCL-1B and Mature T cell Proliferation (MTCP)-1 (Teitell, 2005). All three members of the 
family lack any known enzymatic activity, but they interact with AKT and enhance its 
kinase activity (Pekarsky et al., 2000). Dysregulated expression of the TCL-1 family members 
as a result of chromosome rearrangements is common in a variety of T cell leukemias of the 
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mature phenotype (Pekarsky et al., 2001) and has been also found in Epstein-Barr virus 
positive Burkitt lymphomas (Kiss et al., 2003). Virgilio and coworkers (Virgilio et al., 1998) 
generated transgenic mice with tcl-1 under the control of the lck proximal promoter to 
enforce its expression in T cells. These mice developed T-cell leukemias, thus demonstrating 
that TCL-1 is a bona fide oncogene. Furthermore, transgenic mice with mtcp-1 under the 
control of the T cell specific CD2 promoter also developed T cell leukemia (Gritti et al., 
1998).   
Two other TCL-1 transgenic mouse models extended its transforming capacity to B cells. 
One of these transgenic mice had tcl-1 gene under the control of pE-B29 promoter, causing 
the development of Burkitt-like lymphoma and diffuse large B cell lymphoma (DLBCL) 
(Hoyer et al., 2002). The other model had tcl-1 gene expression under the control of a VH 
promoter and an IgH-E enhancer whose activity targets expression of the transgene to 
immature and mature B cells. The IgH-E-Tcl-1 mice have demonstrated a role for TCL-1 in 
CLL/SLL development (Bichi et al., 2002). Indeed, these mice showed slightly enlarged 
spleens with marginal zone overgrowth, and they developed expanded B220lowIgM+CD5+ B 
cells populations in peripheral blood starting at 6 months of age. All mice around 13-18 
months became visibly ill, presenting splenomegaly, hepatomegaly, and overt leukemia (180 
x 106 cells/ml compared to 2.8 x 106 cells/ml in wild-type littermates). Expanded B cells 
show clonal IgH rearrangements and have low proliferative activity (Bichi et al., 2002). 
Studies on the B cell receptors in the IgH-E-Tcl-1 transgenic mice showed that they 
displayed minimal levels of somatic mutations and resemble those of aggressive, treatment-
resistant human CLL (Yan et al., 2006).  
The demonstration that TCL-1 had a role in CLL development in mice prompted the 
characterization of TCL-1 expression in CLL patients. Indeed, TCL-1 is expressed in the 
majority of CLL (90% by IHC) but shows a differential and regulated expression pattern 
among patients. Higher TCL-1 expression correlates with markers of the pre-germinal center 
subtype including unmutated VH status, ZAP-70 expression and presence of 11q22-23 
deletions. Interestingly, TCL-1 expression was absent in CLL proliferation centers (Herling 
et al., 2006). However, high TCL-1 expression strongly associated to aggressive disease 
features, such as higher white blood cell counts and shorter duplication time (Herling et al., 
2009). In agreement with these data, two independent studies have shown that high TCL-1 
expression correlates with worse disease outcome (Herling et al., 2009), while low TCL-1 
expression showed a trend toward improved complete remission rate after treatment 
(Browning et al., 2007). In agreement with these data, Enzler and coworkers (Enzler et al., 
2009) have found that CLL-like cells from the IgH-E-Tcl-1 transgenic mice have also high 
proliferation rates. However, these cells also have an increased death rate, which slows 
down disease progression. 
AKT is a key component of the BCR signaling, and its activation promotes CLL cell survival 
following BCR engagement (Longo et al., 2008; Petlickovski et al., 2005). Herling and 
coworkers (Herling et al., 2009) have shown that high TCL-1 expression levels are found in 
patients with CLL cells with higher proliferation rates upon BCR engagement. These 
authors found that TCL-1 increases BCR-mediated CLL proliferation by favoring AKT 
recruitment to the activated BCR. Furthermore, decreasing TCL1A levels by small 
interfering RNA reduces AKT activation and sensitizes the fludarabine-resistant CLL cell 
line MEC-2 to fludarabine-triggered apoptosis (Hofbauer et al., 2010) 
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2.2.1 The IgH-E-Tcl-1 transgenic mouse model as a tool for the identification of 
genes involved in CLL progression 
The IgH-E-Tcl-1 transgenic mice have proved to be an invaluable tool to demonstrate in 
vivo the involvement of different genes in the pathogenesis and progression of CLL. Among 
the genes studied so far are the BCR regulators rhoH, pkcand hs1, the TLR regulators id4 
and tir8, and the TNFR family member baff.  
RhoH is a GTPase-deficient member of the GTPase family that facilitates the recruitment of 
ZAP-70 to the immunological synapse. RhoH mRNA expression is slightly upregulated in 
CLL and positively correlates with ZAP-70 expression, a known prognostic marker in CLL 
(Sanchez-Aguilera et al., 2010). To show whether RhoH might have a role in CLL 
progression, IgH-E-Tcl-1(Tg);RhoH-/- mice were generated. In the absence of RhoH 
expression, disease burden and accumulation of CLL cells in blood were delayed. Although 
RhoH-/- B cells showed no defects in BCR signaling, BCR-mediated AKT and ERK 
phosphorylation was reduced in the IgH-E-Tcl-1 (Tg);RhoH -/-  leukemic cells, suggesting a 
cooperation between TCL-1 and RhoH in the control of BCR signaling (Sanchez-Aguilera et 
al., 2010). 
A role for TCL-1 in BCR signaling and its relevance in CLL development and progression 
was further supported with findings showing that IgH-E-Tcl-1 transgenic mice in which 
protein kinase beta (pkc) gene was knocked down failed to develop CLL (Holler et al., 
2009). This result is particularly relevant because PKC is an essential component of the BCR 
signaling complex (Shinohara & Kurosaki, 2009) and its expression and activity is 
upregulated in CLL cells (Abrams et al., 2007).  
Downstream signaling of the BCR in CLL is dominated by the kinases lyn and syk, which 
transduce pro-survival signals after antigen-mediated BCR activation. Lyn was also identified 
as a major contributor to antigen-independent BCR signaling (Contri et al., 2005). Scielzo and 
coworkers (Scielzo et al., 2010) have studied the role in CLL of the hematopoietic cell-specific 
Lyn substrate (HS)-1, a poorly defined component of the Lyn signaling pathway. Their results 
suggest that this protein regulates cytoskeleton remodeling that controls lymphocyte 
trafficking and homing. Mice overexpressing TCL-1 (IgH-E-Tcl-1 tg) were crossed with hs-1 
deficient mice. These mice showed an earlier disease onset and a reduced survival compared 
to the TCL-1-tg mice with normal HS-1 expression levels. The authors concluded that HS-1 
deficiency increases tissue invasion and infiltration capabilities of CLL cells.  
The Inhibitor of DNA binding protein (ID)-4 is a member of the basic helix-loop-helix 
(bHLH) transcription factor family that lacks DNA binding activity but retains the ability to 
bind and inhibit the function of other bHLH proteins, thus conferring ID4 a tumor 
suppressor function (Norton et al., 1998). Chen and coworkers (Chen et al., 2010) have 
shown that ID4 expression is uniformly silenced in CLL cells. The crossing of id4+/- mice 
with IgH-E-Tcl-1 transgenic mice demonstrated that ID4 haploinsufficiency was enough 
to shift CLL to a more aggressive phenotype, as measured by lymphocyte count and 
reduced survival.  Id4 hemizygosity in nontransformed TCL-1 positive B cells protected cells 
from dexamethasone-induced apoptosis and enhanced Toll like receptor (TLR)-9-mediated 
B cell proliferation, suggesting a role for ID4 in apoptosis protection and enhanced immune 
responses to T-independent antigens.   
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Indeed, a role for TLRs in development and progression of CLL has been long suspected 
(Reviewed in (Chiron et al., 2008; Muzio et al., 2009a)). Different TLR agonists, particularly 
those of TLR9, trigger proliferation of unmutated CLL cells, while frequently triggering 
apoptosis of VH mutated CLL cells. Interestingly, these differences observed between 
patients in these two CLL subgroups did not correlate with TLR9 expression levels 
(Jahrsdorfer et al., 2005; Longo et al., 2007; Muzio et al., 2009b), but rather with prolonged 
activation of signaling pathways, including Akt, MAP kinase p38 and NFB. Consistent 
with these data, IgH-E-Tcl-1 transgenic mice with targeted deletion of the gene encoding 
the inhibitory receptor TIR8 (IgH-E-Tcl-1(Tg);tir8-/-), that allows an unabated TLR-
mediated stimulation, developed a more aggressive CLL. The CLL developed by these mice 
was characterized for the appearance of prolymphocytes, reproducing progression of 
human CLL to a terminal phase (Bertilaccio et al., 2011).   
The role of BAFF in promoting CLL in the IgH-Eµ-Tcl-1 transgenic mice will be discussed 
below.  
2.3 Targeted deletion of miR-29 in mice causes indolent CLL 
MicroRNAs (miRs) are endogenous non-coding RNAs 19-25 nucleotides in size that play 
relevant roles in various cellular processes including DNA methylation, cellular growth, cell 
differentiation and apoptosis. They control the expression of specific genes by regulating the 
translation and degradation of target mRNAs (Fabbri et al., 2007). Recent studies revealed 
that nearly half of human miRs are located within fragile sites and genomic regions altered 
in various cancers and there is accumulating evidence of a role for several miRs in the 
etiology of CLL (Calin et al., 2004; Mraz et al., 2009).  
Different lines of evidence suggested that miR-29 should function as an anti-oncogene in 
CLL. First, the expression of the three miR-29 isoforms was downregulated in aggressive 
CLL versus indolent CLL (Calin et al., 2004). Second, miR-29 was shown to target the 
expression of genes implicated in CLL progression and pharmacological resistance, such as 
Tcl-1 (Pekarsky et al., 2006), mcl-1 (Mott et al., 2007), and cdk6 (Garzon et al., 2009).  
Therefore, it came out as a surprise when Santanam and coworkers (Santanam et al., 2010) 
showed that mice with enforced expression of miR-29 under the control of the VH promoter 
and the IgH-E enhancer developed B cell malignancies similar to CLL/SLL. Indeed, clonal 
expansions of CD19+IgM+CD5+ B-cells were found in spleens of a majority (85%) of 12-24 
months old mice. However, only 20% of the mice developed frank leukemia and died of the 
disease. Similar to human patients with indolent CLL, IgH-E-miR-29 transgenic mice were 
immune incompetent, as demonstrated by their inability to mount humoral responses 
against T-dependent antigens, and also contained low levels of IgG in serum.   
Additional studies on miR-29 expression levels in CLL cells from patients showed that 
although miR-29 expression was indeed downmodulated in aggressive versus indolent 
CLL, miR29 level in indolent CLL samples was 4-4.5 fold higher than in normal B cells 
(Pekarsky & Croce, 2010). As discussed by Pekarsky and Croce (Pekarsky & Croce, 2010) 
these results suggest that miR-29 overexpression might predispose to CLL, as demonstrated 
by the miR-29 transgenic mice. However, miR-29 overexpression might preclude 
progression of the disease to more aggressive stages, maybe by targeting TCL-1, whose 
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expression is associated with the most aggressive forms of CLL (see above). Other targets of 
miR-29 might also be implicated in CLL progression, such as MCL-1, CDK6 and peroxidasin 
(Pekarsky & Croce, 2010). New studies to identify the miR-29 targets that are implicated in 
development of indolent CLL seem to be warranted. 
2.4 Mouse models of CLL with dysregulated TNFR family signaling 
TNF-family cytokines and their receptors (TNFRs) regulate a plethora of cellular activities. 
In B cells a restricted group of TNFR family members are expressed, but they tightly 
regulate B cell fate by controlling B cell survival, proliferation and differentiation. 
Dysregulation of these pathways causes severe immune dysfunctions including 
autoimmune disorders (Mackay et al., 2003).  
2.4.1 The Traf2DN/Bcl-2 mouse model of CLL/SLL 
TNF-Receptors Associated Factors (TRAFs) are the molecules that are first recruited to the 
activated TNFR, initially acting as docking molecules for kinases and other effector proteins. 
TRAFs control the subcellular relocalization of the receptor-ligand complex and modulate 
the extent of the response by controlling the degradation of key proteins in the pathway 
(Zapata et al., 2007).  TRAF family members are characterized by a conserved N-terminal 
domain of 180 amino-acid fold coined the TRAF domain, consisting on a bundle of 8 anti-
parallel ǃ-strands that are preceded by an ǂ-helical segment. A total of 6 members of the 
TRAF family participate in the regulation of as many as 20 TNFRs. Some members of the 
family are also involved in the regulation of different members of the Toll-like Receptor 
(TLR) and interleukin-1 receptor (IL-1R) family. Furthermore, TNFR-family members 
generally utilize more than one TRAF family member for signaling, seemingly activating 
similar pathways and even the same downstream effectors. Therefore, the levels of 
expression of the different TRAF-family members and downstream effectors will likely play 
an important role in the outcome of the response. However, there is accumulating evidence 
supporting specific and unique roles for each member of the TRAF family in cell signaling 
(Zapata et al., 2007). 
The first evidence of a direct implication of TRAF dysregulation in tumorigenesis came from 
our laboratory (Zapata et al., 2004). We crossed transgenic mice expressing a TRAF2 mutant 
lacking the N-terminal 240 amino acids encompassing the RING and zinc finger domains 
(TRAF2DN) (Lee et al., 1997) with transgenic mice expressing human BCL-2 specifically in B 
lymphocytes (Katsumata et al., 1992). The Bcl-2 transgene mimics the (14,18)(q32;21) 
translocation involving Bcl-2 and IgH found in human follicular lymphomas. The TRAF2DN 
mutant is defective in the E3 ubiquitin ligase activity that resides in the RING finger 
domain, but it could interact with the receptors (Ha et al., 2009). Single transgenic mice 
overexpressing either BCL-2 or TRAF2DN developed polyclonal expansions of B cells that 
very rarely progressed to malignancy. These mice also had a normal lifespan. The 
Traf2DN/Bcl-2 double transgenic mice were normal at birth. The analysis of B cell 
populations in younger mice demonstrated higher B cell counts and expansion of marginal 
zone B cells, closely resembling those observed in the single Traf2DN-tg mice. However, 
starting at 6 months of age, the Traf2DN/Bcl-2 mice developed severe splenomegaly and 
lymphadenopathy, and most animals also developed leukemia (as many as 130 x 106 B 
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cells/ml), pleural effusion, and, in some cases, ascites associated with monoclonal and 
oligoclonal B cell neoplasms. The expanded B cell population of Traf2DN/Bcl-2 double-
transgenic mice was primarily comprised of small/medium-size non-cycling 
B220MediumIgMhighCD5+CD11b+ cells. Transformed B cells also had high expression levels of 
the adhesion molecules CD49d, CD29, CD54, and CD11a in the surface, compared to wild-
type B cells. Histopathologic features were consistent with mouse small lymphocytic 
lymphoma (SLL) progressing to leukemia with many similarities to human chronic 
lymphocytic leukemia. By month 14, as many as 80% of the mice died from the disease 
(Kress et al., 2007; Zapata et al., 2004). 
B cells from the Traf2DN/Bcl-2 double-transgenic did not show any increase in 
proliferation in culture compared to B cells either from the Traf2DN or the Bcl-2 single 
transgenic mice and wild-type littermates. However, consistent with the overexpression 
of BCL-2, Traf2DN/Bcl-2 B cells were partially resistant to apoptosis induced by 
chemotherapeutic drugs, such as dexamethasone and fludarabine. Interestingly, 
TRAF2DN B cells were also partially resistant to apoptosis induced by these drugs, 
suggesting that functional inhibition of TRAF2 might provide survival advantage to B 
cells (Zapata et al., 2004).  
BCL-2 overexpression is a hallmark of many lymphoid malignancies, including CLL. BCL-2 
protects transformed cells from apoptosis favoring disease progression and contributing to 
drug resistance (Buggins and Pepper, 2010; Reed, 2008). However, the role in tumorigenesis 
of dysregulated TRAF2 pathways is less characterized (Zapata et al., 2007). We have 
continued our studies to assess the role of TRAF2DN in B cell transformation and have 
shown that expression of the Traf2DN transgene causes proteosome-dependent degradation 
of endogenous TRAF2 (manuscript in preparation). Therefore, the TRAF2DN mice are 
indeed TRAF2 deficient mice. TRAF2DN B cells have deficient JNK activation and 
constitutive activation of the non-canonical NFB pathway (NFB2) (manuscript in 
preparation). B cell-specific Traf2-defficient mice have been already described (Gardam et 
al., 2008; Grech et al., 2004).  Similar to Traf2DN and Traf2DN/Bcl-2 mice, the TRAF2-/- mice 
also have expansion of marginal zone B cells. Furthermore, B cells from these mice are also 
deficient in JNK activation, have constitutive NFB2 activation and are more resistant to 
apoptosis (Gardam et al., 2008; Grech et al., 2004).  
Interestingly, Zhang and coworkers (Zhang et al., 2007) have provided proof of the direct 
involvement of dysregulated NFB2 in the development of SLL/CLL. These authors 
developed transgenic mice expressing in lymphocytes p80HT, a lymphoma-associated 
NFB2 mutant (Kim et al., 2000). These mice displayed a marked expansion of peripheral 
B cell populations and developed SLL. B cells from these mice were also resistant to 
apoptosis induced by cytokine deprivation and mitogenic stimulation. However, these 
authors also developed transgenic mice overexpressing in B cells p52, the active subunit 
of NFB2 normally produced upon activation. These mice were predisposed to 
inflammatory autoimmune disease. Mice with the disease contain high levels of 
autoantibodies in serum and immune complex glomerulonephitis (Wang et al., 2008). 
These results place NFB2 in the crossroad of autoimmunity and CLL and suggest that 
proteins controlling the transcriptional specificity of NFB2 might function as a switch for 
autoimmunity or CLL.  
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Altogether, our results suggest that in the Traf2DN/Bcl-2 transgenic mouse model of 
SLL/CLL, Traf2-deficiency might increase the resistance of subsets of B cells to apoptosis 
induced by specific TNF-family members. It is also conceivable that upon B cell activation 
(by antigen, for instance), the absence of functional TRAF2 might direct stimulated B cells 
through alternative maturation pathways, while overexpression of BCL-2 would protect 
these B cells from apoptotic stimuli involving the intrinsic pathway, ultimately promoting 
the development of malignancies.  
2.4.2 BAFF and APRIL models of CLL/SLL 
BAFF (B cell activating factor; TNFSF13b) and APRIL (a proliferation-inducing ligand; 
TNFSF13) are two closely related TNF family members that bind the members of the TNFR 
family BCMA (B cell maturation antigen) and TACI (transmembrane activator of the calcium 
modulator and cyclophilin ligand interactor). BAFF, but not APRIL, can also interact with 
BAFF-receptor (BAFFR), another TNFR family member, which seems to be the preferential 
receptor for BAFF (Mackay et al., 2007; Planelles et al., 2008) (Figure 1). BAFF overexpression is 
causative of autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid 
arthritis and Sjögren's syndrome in both human and mice. Indeed, three different BAFF-
transgenic mice were produced independently by three different laboratories, and all three 
developed SLE-like disease (Gross et al., 2000; Khare et al., 2000; Mackay et al., 1999). 
Furthermore, BAFF and APRIL have been shown to support chronic lymphocytic leukemia 
survival in a mechanism that seems to implicate BCMA and TACI and the activation of the 
canonical NFB pathway (Endo et al., 2007). Elevated serum levels of APRIL have been found 
in CLL patients, and high APRIL levels correlate with poor prognosis (Planelles et al., 2007). 
Both BAFF and APRIL are produced by nurselike cells (Nishio et al., 2005) and BAFF is also 
produced by proliferating prolymphocytes in the CLL proliferation centers of the lymph nodes 
(Herreros et al., 2010), suggesting that BAFF might provide autocrine and paracrine protection 
to CLL cells in the lymph node microenvironment. Altogether, these results suggest that BAFF 
and APRIL might sustain CLL cell survival (Figure 1). 
We have mentioned above that CLL-like cells from the IgH-E-Tcl-1 transgenic mice have 
unexpected high proliferation rates compared to non-transformed lymphocytes (Enzler et 
al., 2009). However, disease progression in these mice was slow, which might be a 
consequence of the high death rate of the transformed B220lowIgMhighCD5+ cells as 
demonstrated by TUNEL staining of the spleens of these mice. Enzler and coworkers (Enzler 
et al., 2009) produced double transgenic IgH-E-Tcl-1/Baff mice to investigate whether BAFF 
could exacerbate the disease. Indeed, these mice developed CLL at a significantly younger 
age and had more rapid disease progression and shorter survival compared to IgH-E-Tcl-1 
transgenic mice. As expected, BAFF protected CLL cells from apoptosis without having any 
effect on the proliferation rates of CLL cells. 
Another interesting mouse model of CLL overexpressing both BAFF and c-Myc was recently 
described by Zhang and coworkers (Zhang et al., 2010). Transgenic mice with c-Myc under 
the control of the IgE enhancer (iMycC-tg) were initially generated to enforce c-Myc 
expression in plasma cells and memory cells (Cheung et al., 2004). Zhang and coworkers 
(Zhang et al., 2010) asked whether BAFF overexpression in these mice could induce 
development of CLL, since recent evidence indicates that CLL cells might arise from 
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memory B cells (Klein et al., 2001). Interestingly, male c-Myc/Baff double transgenic mice did 
indeed developed lymphocytosis starting at 3 months of age because of increased blood B-
cell number relative to that observed for single transgenic, wild type or female double 
transgenic mice. By month 8, clonal expansions of CD3−B220lowCD5+ cells were observed in 
as many as 78% of male c-Myc/Baff mice, but only in 9% of females. Mice also developed 
splenomegaly, lymphadenopathy and bone marrow infiltration. Histochemical and 
morphological analyses of the tumor populations were consistent with CLL/SLL. This 
mouse model of CLL is particularly interesting because is the only mouse model of 
CLL/SLL that mimics the gender bias observed in human patients, with a higher incidence 
of the disease in males.  
 
Fig. 1. Schematic representation of the signal transduction pathways and activities induced by 
APRIL, BAFF and their receptors.  BAFF is the main ligand for BAFF-R, but it can also interact 
as a multimerized ligand with TACI and BCMA. APRIL is the ligand for TACI and BCMA, 
although it has a higher affinity for TACI. Signaling from all three receptors is mediated by 
members of the TRAF family. TRAF3 seems to be the only TRAF-family member capable to 
directly interact with BAFF-R, but TRAF2 is crucial to control the extent of BAFF-R-mediated 
NFB2 activation (Gardam et al., 2008; Grech et al., 2004). Different members of the TRAF-
family, including TRAF2 and 3, seem to interact with the cytosolic tail of BCMA and TACI and 
to regulate the activation of the canonical NFB pathway (NFB1) and MAPKs. Engagement 
of BAFF-R and TACI also induces AKT activation. CLL cells seem to express all three 
receptors, and BAFF and APRIL have been shown to support chronic lymphocytic leukemia 
survival in a mechanism that seems to implicate the activation of the canonical NFB pathway 
(Endo et al., 2007). For additional information, see (Mackay et al., 2007; Planelles et al., 2008; 
Mackay & Schneider, 2008, 2009; Kimberley et al., 2009).  
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As stated above, elevated serum levels of APRIL have been found in CLL patients, and high 
APRIL levels seem to correlate with poor prognosis (Planelles et al., 2007).  Planelles and 
coworkers (Planelles el al., 2004) have shown that transgenic mice with April under the control 
of the lck promoter developed progressive hyperplasia in mesenteric lymph nodes and Peyer’s 
patches, disorganization of affected lymphoid tissues, and mucosal and capsular infiltration. 
Tumor cells will eventually infiltrate non-lymphoid tissues, such as kidney and liver in some 
of the mice. The expanded B cell population is B220lowIgM lowCD5+ and CD23- , which seems to 
indicate that these cells have a peritoneal B-1 origin. The incidence of the most severe 
pathologies was low (25%) and there was no evidence that these pathologies caused any 
reduction in lifespan. Although the authors did not assess whether B cell expansions in the 
April-tg mice were monoclonal or polyclonal, this model demonstrates that APRIL is a survival 
B cell factor in vivo and supports a role for APRIL in CLL progression.   
Furthermore, pharmacological inhibition of the IKK-NFB axis could prevent the pro-
survival effect of BAFF overexpression in these mouse models, thus highlighting the role of 
the canonical NFB pathway in CLL survival. Interestingly, TCL-1 might function as a 
transcriptional regulator controlling AP-1 and NFB activity. Indeed, TCL-1 has been shown 
to inhibit AP-1 transcriptional activity by interacting with c-Jun, JunB and c-Fos, and to 
increase NFB activity by physically interacting with p300/CREB binding protein (Pekarsky 
et al., 2008). Recent studies on the epigenetic changes occurring in the Tcl-1 transgenic B cells 
show that NFB1-dependent inactivation of Foxd3 expression is an early epigenetic event 
causing the silencing of target genes that might be implicated in CLL development (Chen et 
al., 2009).   
Finally, it is interesting to mention that DLEU7, a gene in the 13q14 deletion region which is 
also downregulated in other subtypes of CLL (Ouillette et al., 2008) (see below), seems to 
inhibit TRAF-mediated NFB and nuclear factor of activated T cells (NFAT) activation. The 
mechanism might involve LEU7 interaction with BCMA and TACI (transmembrane 
activator of the calcium modulator and cyclophilin ligand interactor) (Palamarchuk et al., 
2010) thus preventing TRAF-interaction with the activated receptors. The authors proposed 
that inhibition of DLEU expression might increase NFB activation and apoptosis resistance. 
2.5 Mice with deletions of the DLEU2/miR15a/16-1 cluster 
Among the genomic aberrations that are found in CLL patients, the most common (55%) is 
deletion of 13q14 (Bullrich et al., 1996; Dohner et al., 2000; Kalachikov et al., 1997; 
Stilgenbauer et al., 2000). In the vast majority (76%) of CLL cases this deletion is monoalellic, 
and only 24% are biallellic (Dohner et al., 2000). Similar frequencies of  this deletion (50%) 
are also found in mantle cell lymphoma and at lower frequency in DLBCL, multiple 
myeloma,  mature T cell lymphomas (Capello & Gaidano, 2000) and in a variety of solid 
tumors (Dong et al., 2001) which is indicative of its relevance in disease.  
Studies with large cohorts of CLL patients harboring monoalellic 13q14 deletions allowed 
the identification of a 10 Kb minimal deleted region (MDR) common to all CLL patients (Liu 
et al., 1997; Migliazza et al., 2001) (Figure 2). In humans, this region contains the noncoding 
RNA gene (DLEU)-2, miR-15a and miR16-1 (Calin et al., 2008), that are expressed as a cluster 
under the control of the DLEU2 promoter (Klein & Dalla-Favera, 2010).  
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The relevance in pathogenesis of this minimal 13q14 deletion has been elegantly 
demonstrated by Klein and coworkers (Klein et al., 2010). These authors have generated 
mice that have deletion of either the MDR (encompassing the whole DLEU2 gene including 
the miR15a/16-1 cluster in its intron 4) or the miR15a/16-1 only. Young MDR-/- and miR15a/16-
1-/- mice showed no differences in B cell populations compared to wild-type mice, indicating 
the lack of involvement of this gene cluster in B cell development. These mice also mounted 
normal T-dependent antigen responses, suggesting that antigen-driven B cell differentiation 
is not affected by any of these deletions. However, as these mice grew older (15-18 months), 
they develop CD5+ B cells lymphoproliferative disorders, the most frequent being 
CLL/SLL, which could be detected in 27% of MDR-/- mice and in 21% of miR15a/16-1-/- mice. 
As many as 5% of these mice developed clonal expansions of B220low CD5+ B cells in 
peripheral blood, closely resembling human monoclonal B cell lymphocytosis. Furthermore, 
a fraction of MDR-/- (9%) and miR15a/16-1-/- (2%) mice developed CD5null NHL of splenic 
and/or lymph node origin, the majority of which were histologically similar to DLBCL, thus 
resembling Richter‘s transformation of human CLL patients (Foucar & Rydell, 1980). The 
rest of NHL lymphomas developed by these mice were similar to plasmacytic lymphomas 
(Klein et al., 2010).    
 
Fig. 2. Schematic representation of the minimal deletion region (MDR) in human 13q14 and 
the corresponding region in mouse 14qC3. Deleted genomic regions in MDR-deficient and 
miR15a/16-1-deficient mice are shown. Adapted from (Klein et al., 2010).  
Interestingly, the mice with the MDR deletion not only displayed a larger incidence of 
disease (42% for the MDR-/- and 24% for the MDR+/-), but they also had a reduced lifespan 
(around 70% of the MDR-/- mice and 50% of the MDR+/- died by month 20), compared to 
miR15a/16-1-/- mice, which had an overall 26% tumor incidence and no significant lifespan 
reduction compared to wild-type littermates. Thus, these results support a role for 
miR15a/16 as tumor suppressor, but also indicate that there might be additional genetic 
elements within the MDR locus implicated in the etiology of CLL.  
The analysis of the genes targeted by miR15a/16-1 was also assessed by Klein and 
coworkers (Klein et al., 2010) in B cells from the miR15a/16-1-/- mice. Their results showed the 
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role of this miR cluster in the regulation of cell proliferation through the control of the 
expression of cyclins and other genes involved in cell cycle progression, as previously 
described in a variety of cell types (Bandi et al., 2009; Bonci et al., 2008; Linsley et al., 2007; 
Liu et al., 2008). Using a green fluorescence protein lentiviral expression system, Salerno and 
coworkers (Salerno et al., 2009) further demonstrated the direct targeting of Cyclin D1 3’ 
unstranslated region by miR16.  
Of special interest is the role of miR15a/16-1 in the regulation of BCL-2 expression.  As 
stated above, BCL-2 is a pro-survival protein that is upregulated in several lymphoid 
malignancies, including CLL/SLL (Reed, 2008). Indeed, enforced BCL-2 overexpression in 
mice predisposes to CLL/SLL (Zapata et al., 2004), although its overexpression alone is not 
sufficient for CLL development (Katsumata et al., 1992). High levels of BCL-2 are a 
trademark of CLL but the mechanism underlying BCL-2 overexpression in CLL/SLL 
remains unclear. Cimmino and coworkers (Cimmino et al., 2005) showed evidence 
indicating that miR15a/16-1 targeted BCL-2 mRNA, and found an inverse correlation 
between miRNA15/16 and BCL-2 expression levels. However, other studies (Fulci et al., 
2007; Ouillette et al., 2008) failed to find such correlation and showed that down-regulation 
of both miR15a and 16-1 was not paralleled by any significant increase in BCL-2 levels. In 
this regard, the studies by Klein and coworkers (Klein et al., 2010) showed that neither 
deletion of MDR or miR15a/16-1 had any significant effect on BCL-2 expression when 
compared to that of B cells from wild-type littermates. Upregulation of BCL-2 expression in 
germinal centers was also unaffected in MDR-/- and miR15a/16-1-/- mice. Although 
additional studies are needed to elucidate whether miR15a/16-1 expression might regulate 
BCL-2 expression in specific cell contexts and physiological situations, it seems unlikely that 
miR15a/16-1 downregulation accounts for BCL-2 upregulation in CLL.   
In summary, these results strongly suggest that the main physiological role of miR15a/16-1 
is to regulate cell homeostasis by controlling the expression of proteins implicated in cell 
cycle progression.  However, similar to the IgH-E-TCL-1 mice, where high CLL 
proliferation rates were compensated with increased cell death rates (Enzler et al., 2009), 
efficient transformation of cells bearing the 13q14 deletion might require also the 
cooperation of pro-survival factors.  
2.6 A SV40 T antigen-driven mouse model of CLL  
Ter Brugge and coworkers (ter Brugge et al., 2009) reported a new mouse model based on 
expression of the simian virus 40 (SV40) large T antigen. These authors generated 2 different 
mouse models introducing the SV40 T gene in the immunoglobulin heavy chain locus 
between the D and J segments, in opposite transcriptional orientation. SV40 T expression 
was enforced in each mouse model by either 1 or 2 copies of the IgH intronic enhancer Eμ. 
The levels of SV40 T expression were higher in the transgenic mice with two copies of the Eμ 
enhancer. Mice carrying two copies of the Eμ enhancer developed clonal expansions of 
mature B cells in blood, lymph nodes, spleen, and bone marrow before the age of 10 months. 
In contrast only 10% of the mice carrying only one copy of the enhancer developed this 
malignancy. Expanded B cells were CD19+IgMhighCD5+CD43+, consistent with CLL. In 
addition, DNA sequencing analysis determined that VH regions were either unmutated, 
with preferential usage of the VH11, or showed extensive somatic hypermutation and usage 
of VHJ558.  
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SV40 large T protein interacts with numerous cellular proteins and pathways, most notably 
the Retinoblastoma and p53 pathways (Ahuja et al., 2005; Ali & DeCaprio, 2001), although in 
this model, p53 expression seems to be deleterious for the transforming activity of the T 
protein (ter Brugge et al., 2009).  Similar to TCL-1 (see above), SV40 large T protein has been 
shown to induce cell survival via AKT activation (Cacciotti et al., 2005).   
2.7 Transplantation models of CLL 
2.7.1 Xenograft models 
Development of xenograft models of human CLL cells has been a troublesome task as a 
result of the non-proliferative nature of circulating CLL cells. Initial approaches involved 
transferring CLL cells from patients into mice with severe combined immunodeficiency 
(SCID). A percentage of these mice developed tumors, but they were composed by CD5- 
EBV+ B cells, emulating the EBV-associated lymphoproliferations noted in SCID mice 
reconstituted with normal human PBL (Kobayashi et al., 1992).  Intraperitoneal injections of 
IL-2 and IL-7 in SCID mice previously inoculated with human CLL failed to improve the 
efficacy of this type of engraftment (Hummel et al., 1996).  Shimoni and coworkers (Shimoni 
et al., 1997) used lethally irradiated Balb/c or beige/nude/Xid (BNX) mice radioprotected 
with bone marrow from SCID mice as engraftment recipients for human CLL cells. These 
authors found that adoptive transfer of low-stage CLL peripheral blood mononuclear cells 
(PBMCs) (Rai 0) led to marked engraftment of T cells or combined T and CLL cell 
engraftment, whereas inoculation of high-stage (III-IV) CLL PBMCs led to dominance of 
CLL cells with negligible involvement of T cells. These authors succeeded in transplanting 
low-stage CLLs by depleting T cells from the PBMC culture using OKT3 antibody. In 
contrast, eliminating T cells was not as critical for promoting engraftment of high-stage CLL 
cells (Shimoni et al., 1999). The authors concluded that autologous T cells can actively 
suppress the expansion of CLL in the mouse recipient. Indeed, Durig and coworkers (Durig 
et al., 2007) obtained similar results using sublethally irradiated nonobese diabetes 
(NOD)/SCID mice as recipients for CLL xenotransplantation. These authors combined 
intra-peritoneal and intra-venous injections of PBMCs from CLL patients, achieving a highly 
reproducible splenic and peritoneal engraftment that remained stable for 4-8 weeks. 
However, these authors also reported that PBMCs from CLL donors with Binet stage A 
favored T cell engraftment over CLLs. In contrast, predominant engraftment of CLL cells 
was achieved using PBMCs from CLL patients with Binet stage C. 
Recent data, however, put into question the deleterious role of autologous T cells in CLL 
engraftment. Bagnara and coworkers (Bagnara et al., 2011) have described a novel adoptive 
transfer model of chronic lymphocytic leukemia in which primary CLL cells proliferate in 
NSG (NOD/SCID/IL2Rγ-/-) mice under the influence of activated CLL-derived T 
lymphocytes. The NSG recipient mouse strain is a NOD/SCID-derived strain that lacks the 
IL-2 family common cytokine receptor gamma chain gen (IL2RǄ), rendering mice 
completely deficient in lymphocytes (including NK cells). The authors have shown that by 
co-transferring autologous T lymphocytes, activated in vivo by alloantigens, the survival and 
growth of primary CLL cells in vivo could be achieved and quantified. However, although T 
cells are required for CLL survival and proliferation, eventually all human CLL cells 
disappeared and the animal died after 12 weeks by T cell-dependent graft versus host 
disease. Although it has some significant limitations, this mouse model should simplify 
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analyzing kinetics of CLL cells in vivo and permitting personalized preclinical studies of 
novel therapeutics. 
Kikushige and coworkers (Kikushige et al., 2011) have recently used xenogeneic 
transplantation of different CLL subpopulations to demonstrate that the propensity to 
generate clonal B cells is already acquired at the hematopoietic stem cell (HSC) stage. These 
authors transplanted either mature CLL cells, purified proB cells or purified HSCs from CLL 
patients into NSG or into NOD/Rag1-/- IL2Rγ-/- (NRG) mice. CLL cells or proB cells from 
patients failed to engraft in any of the xenotransplanted mice, but CLL-HSCs, similar to 
normal donors HSCs, were able to reconstitute the hematopoietic lineages in the mice. 
However, contrary to normal donors HSCs, CLL-HSCs differentiation in xenotransplanted 
mice seemed to be skewed toward B cell lineage and B cell maturation was always restricted 
to mono- or oligo-clones with CLL-like phenotype, thus suggesting that HSCs could be 
involved in leukemogenesis even in mature lymphoid tumors.    
Finally, Bertilaccio and coworkers (Bertilaccio et al., 2010) have described the engraftement of 
the CLL cell line MEC1 in Rag2-/- IL2Rγ-/- mice This xenograft mouse model has systemic organ 
involvement, develops very rapidly, allows the measurement of tumor burden, and has 100% 
engraftment efficiency, thus closely resembling aggressive human disease. This mouse model 
has also been used to study the role of the Lyn substrate HS1 in CLL (Scielzo et al., 2010). 
2.7.2 Allograft models 
Nakagawa and coworkers (Nakagawa et al., 2006b) have demonstrated a role for PKCǂ in 
the etiology of CLL using a new approach involving allogeneic transplantation. These 
authors stably expressed a plasmid encoding a dominant-negative PKCǂ (PKCǂ-KR) 
mutant in fetal liver-derived hematopoietic progenitor cells (HPC) from wild-type mice. 
Interestingly, in vitro and in vivo expansion of these cells in transplanted Rag-/- mice resulted 
in the generation of a population of B cells expressing B220+IgMlowCD5+CD23+ resembling 
human CLL cells.  Compared to untransfected cells, these CLL-like cells display enhanced 
proliferation in the presence of growth factors and stroma and apoptosis resistance, which 
seems to be mediated by BCL-2 overexpression. Furthermore, other PKC family members 
did not cause this transformation, thus highlighting the role of PKCǂ as a tumor suppressor 
in CLL. This model of “instant transgenesis” is particularly interesting because it allows 
determining the role of specific signaling molecules during lymphocyte development in vivo 
by introducing a defined gene, such as a wild-type or mutated signaling molecule, into a 
lymphoid progenitor population by retroviral infection that could be expanded in vivo in 
recipient Rag -/- mice (Nakagawa et al., 2006a).  
2.8 Mouse models of CLL as preclinical platforms for testing new chemotherapeutic 
drugs 
Preclinical studies of new drug candidates would benefit from the availability of mouse 
models of CLL that closely recapitulate key aspects of the disease as seen in humans. 
Indeed, the IgH-E-Tcl-1 and the Traf2DN/Bcl-2 transgenic mice have been already used to 
test the anti-CLL efficacy of new drugs in mice. Thus, the IgH-E-Tcl-1 transgenic mice were 
used to assess the efficacy of fludarabine, a drug used as a first line of treatment of CLL 
patients, in the leukemic mice (Johnson et al., 2006). Fludarabine was shown to be clinically 
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active at low dose in the mice, reducing leukemic burden. However, an emergence of 
resistance over repeated treatments was observed in the mice, similar to what happens to 
CLL patients (Johnson et al., 2006).  
Furthermore, cells from the IgH-E-Tcl-1 mice were transplanted into syngeneic mice to test 
the in vivo efficacy of rapamycin, a specific pharmacologic inhibitor of the AKT/mTOR 
pathway, in the progression of the disease (Zanesi et al., 2006). Treatment with rapamycin 
significantly prolonged the life of all treated animals compared to untreated mice. However, 
the delaying effect of rapamycin on mouse CLL was relatively short and, eventually,  all 
mice died from the disease. A similar approach was also used to show the anti-leukemic 
activity of fosfamatinib disodium (R788), a Syk inhibitor that blocks BCR signaling (Suljagic 
et al., 2010). R788 effectively reduced proliferation and survival of the malignant cells 
without affecting normal B lymphocytes. (Suljagic et al., 2010).  
Traf2DN/Bcl-2 mice served also as a preclinical platform to test the anti-CLL efficacy of the 
synthetic triterpenoid 2-Cyano-3,12-Dioxooleana-1,9-Dien-28-Oic Acid (CDDO) and its 
imidazolide derivative (CDDO-Im). Treating Traf2DN/Bcl-2 mice that had developed 
leukemia with liposome-formulated CDDO or CDDO-Im resulted in significant 
amelioration of CLL/SLL burden by dramatically reducing malignant B cells in blood, 
spleen and lung, without having any significant effect on the viability of normal B and T 
cells (Kress et al., 2007).  
3. Conclusion 
The different genetically modified mice or natural strains described above have provided 
valuable insights into the molecular mechanisms behind CLL/SLL transformation and 
progression. They have also demonstrated that it is possible to develop mouse models that 
share defining characteristics with specific human CLL subsets. Just as an example, Tcl-1-tg 
mice might be counterpart of aggressive CLL, miR29 tg mice seem to be related to indolent 
CLL, and the Traf2DN/Bcl-2-tg mice might be a good model of refractory disease.  
The results and conclusions achieved from the studies with mice might not always be 
extrapolated to human, and vice versa. However, preclinical studies performed in CLL/SLL 
mouse models of specific CLL subclasses would be a leap forward in our understanding of 
the biological behavior and specificity of new chemotherapeutic drug families. These studies 
will help to determine in vivo not only the efficacy of the drug, but also to identify potential 
problems with the therapy, such as lysis shock, high protein binding, first pass effect and 
non-appropriate biodistribution of the drug that may limit its efficacy. 
Future studies in the mouse models described in this chapter and in others still to be 
developed will expand our understanding of CLL etiology and will provide new tools for 
fighting the disease. 
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